Patents by Inventor Amy E. Tapper

Amy E. Tapper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20230250090
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: December 15, 2022
    Publication date: August 10, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, JR.
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20230104647
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive amination of cyclopropylamines.
    Type: Application
    Filed: June 15, 2022
    Publication date: April 6, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11578059
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 14, 2023
    Assignee: Imago Biosciences. Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • Methods and processes for the preparation of KDM1A inhibitors
    Patent number: 11390590
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 19, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20220073477
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES
    Publication number: 20220025424
    Abstract: The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 27, 2022
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth C.A. BROT, Peter C. MICHELS, Venkat K. CHARI, Ian C. COTTERILL
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11230534
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 25, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20210139437
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Application
    Filed: August 16, 2017
    Publication date: May 13, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20210115023
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1 A for the treatment or prevention of diseases. Methods of inhibition of KDM1 A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 22, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, Jr.
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20200283397
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: November 1, 2019
    Publication date: September 10, 2020
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10519118
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 31, 2019
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20180312474
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: April 12, 2018
    Publication date: November 1, 2018
    Inventors: Hugh Y. RIENHOFF, Jr., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A inhibitors for the treatment of disease
    Patent number: 9981922
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 29, 2018
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20160237043
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: February 12, 2016
    Publication date: August 18, 2016
    Inventors: Hugh Y. Rienhoff, JR., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • POLYMORPH FORMS OF DESAZADESFERRITHIOCIN ANALOGS
    Publication number: 20150299151
    Abstract: The present invention provides a solid form and compositions thereof, which are useful as metal chelators and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: December 6, 2013
    Publication date: October 22, 2015
    Applicant: FerroKin BioSciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres
  • Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
    Patent number: 8846731
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogs, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 30, 2014
    Assignee: FerroKin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
    Patent number: 8829197
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: September 9, 2014
    Assignee: FerroKin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • Salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
    Patent number: 8710087
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: April 29, 2014
    Assignee: Ferrokin Biosciences, Inc.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS
    Publication number: 20120270911
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: October 6, 2011
    Publication date: October 25, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, Jr., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang
  • NOVEL SALTS AND POLYMORPHS OF DESAZADESFERRITHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS
    Publication number: 20120202857
    Abstract: Disclosed herein are new salts and polymorphs of desazadesferrithiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
    Type: Application
    Filed: August 4, 2011
    Publication date: August 9, 2012
    Applicant: FERROKIN BIOSCIENCES, INC.
    Inventors: Amy E. Tapper, Hugh Y. Rienhoff, JR., Stephan D. Parent, Patricia Andres, Jason A. Hanko, Huamin Zhang